120 related articles for article (PubMed ID: 26561496)
21. Pharmacokinetics and Pharmacodynamics of Atazanavir in HIV-1-Infected Children Treated With Atazanavir Powder and Ritonavir: Combined Analysis of the PRINCE-1 and -2 Studies.
Sevinsky H; Zaru L; Wang R; Xu X; Pikora C; Correll TA; Eley T
Pediatr Infect Dis J; 2018 Jun; 37(6):e157-e165. PubMed ID: 29206748
[TBL] [Abstract][Full Text] [Related]
22. Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection.
Crutchley RD; Guduru RC; Cheng AM
HIV AIDS (Auckl); 2016; 8():47-65. PubMed ID: 27022304
[TBL] [Abstract][Full Text] [Related]
23. Cardiovascular risk in advanced naïve HIV-infected patients starting antiretroviral therapy: Comparison of three different regimens - PREVALEAT II cohort.
Maggi P; Bellacosa C; Leone A; Volpe A; Ricci ED; Ladisa N; Cicalini S; Grilli E; Viglietti R; Chirianni A; Bellazzi LI; Maserati R; Martinelli C; Corsi P; Celesia BM; Sozio F; Angarano G
Atherosclerosis; 2017 Aug; 263():398-404. PubMed ID: 28522147
[TBL] [Abstract][Full Text] [Related]
24. Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAzanavir & GLUcose metabolism (ATAGLU) study.
d'Ettorre G; Ceccarelli G; Zaccarelli M; Ascoli-Bartoli T; Bianchi L; Bellelli V; De Girolamo G; Serafino S; Giustini N; Mastroianni CM; Vullo V
Int J STD AIDS; 2016 Jul; 27(8):638-43. PubMed ID: 26068963
[TBL] [Abstract][Full Text] [Related]
25. Safety and Efficacy of Atazanavir Powder and Ritonavir in HIV-1-Infected Infants and Children From 3 Months to <11 Years of Age: The PRINCE-2 Study.
Cotton MF; Liberty A; Torres-Escobar I; Gonzalez-Tome MI; Lissens J; Zaru L; Klauck I; Cambilargiu D; Pikora C; Correll TA
Pediatr Infect Dis J; 2018 Jun; 37(6):e149-e156. PubMed ID: 29206747
[TBL] [Abstract][Full Text] [Related]
26. Confirmation of the drug-drug interaction potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives.
Majeed SR; West S; Ling KH; Das M; Kearney BP
Antivir Ther; 2019; 24(8):557-566. PubMed ID: 31933482
[TBL] [Abstract][Full Text] [Related]
27. The DIANA Study: Continued Access to Darunavir/Ritonavir (DRV/r) and Long-Term Safety Follow-Up in HIV-1-Infected Pediatric Patients Aged 3 to < 18 Years.
Violari A; Masenya M; Blanche S; Vanveggel S; Hufkens V; Chetty P; Opsomer M
Drug Saf; 2021 Apr; 44(4):439-446. PubMed ID: 33367975
[TBL] [Abstract][Full Text] [Related]
28. Atazanavir and darunavir in pregnant women with HIV: evaluation of laboratory and clinical outcomes from an observational national study.
Floridia M; Masuelli G; Ravizza M; Tassis B; Cetin I; Sansone M; Degli Antoni A; Simonazzi G; Maccabruni A; Francisci D; Frisina V; Liuzzi G; Dalzero S; Tamburrini E;
J Antimicrob Chemother; 2018 Apr; 73(4):1025-1030. PubMed ID: 29244115
[TBL] [Abstract][Full Text] [Related]
29. Factors involved in continuance of atazanavir-based regimens: Results from a cohort of HIV1-positive patients.
Giacomelli A; Oreni L; Franzetti M; Di Cristo V; Colella E; Ridolfo AL; Galli M; Rusconi S
Antiviral Res; 2016 May; 129():52-57. PubMed ID: 26902109
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.
Madeddu G; Rusconi S; Cozzi-Lepri A; Di Giambenedetto S; Bonora S; Carbone A; De Luca A; Gianotti N; Di Biagio A; Antinori A;
Infection; 2017 Aug; 45(4):521-528. PubMed ID: 28477212
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and 48-week safety and efficacy of generic ritonavir tablet-boosted atazanavir in HIV-1-infected Thai adults.
Hiransuthikul A; Thammajaruk N; Techatanawat I; Karachot B; Chuasuwan B; Manamuti C; Duereh M; Sawpitiporn M; Sophonphan J; Gatechompol S; Avihingsanon A; Bowonwattanuwong C; Ruxrungtham K;
Antivir Ther; 2018; 23(8):699-703. PubMed ID: 30265243
[TBL] [Abstract][Full Text] [Related]
32. Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial.
Gallant J; Moyle G; Berenguer J; Shalit P; Cao H; Liu YP; Myers J; Rosenblatt L; Yang L; Szwarcberg J
Curr HIV Res; 2017; 15(3):216-224. PubMed ID: 27774892
[TBL] [Abstract][Full Text] [Related]
33. Incidence of atazanavir- associated adverse drug reactions in second -line drugs treated south Indian HIV-1 infected patients.
Subashini D; Dinesha TR; Boobalan J; Samuel LC; Poongulali S; Pradeep A; Solomon SS; Solomon S; Balakrishnan P; Saravanan S
Indian J Pharmacol; 2016; 48(5):582-585. PubMed ID: 27721547
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus.
Navarro J; Santos JR; Silva A; Burgos J; Falcó V; Ribera E; Imaz A; Curran A
Pharmacotherapy; 2019 Apr; 39(4):501-507. PubMed ID: 30723941
[TBL] [Abstract][Full Text] [Related]
35. Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial.
Bunupuradah T; Kiertiburanakul S; Avihingsanon A; Chetchotisakd P; Techapornroong M; Leerattanapetch N; Kantipong P; Bowonwatanuwong C; Banchongkit S; Klinbuayaem V; Mekviwattanawong S; Nimitvilai S; Jirajariyavej S; Prasithsirikul W; Munsakul W; Bhakeecheep S; Chaivooth S; Phanuphak P; Cooper DA; Apornpong T; Kerr SJ; Emery S; Ruxrungtham K;
Lancet HIV; 2016 Aug; 3(8):e343-e350. PubMed ID: 27470026
[TBL] [Abstract][Full Text] [Related]
36. Long-term clinical experience with darunavir (2007-2015) in a large cohort of HIV-infected patients in Spain.
Pernas B; Grandal M; Tabernilla A; Cid P; Pértega S; Castro-Iglesias Á; Mena Á; Margusino L; Pedreira JD; Poveda E
J Med Virol; 2016 Dec; 88(12):2125-2131. PubMed ID: 27218208
[TBL] [Abstract][Full Text] [Related]
37. Impact of darunavir, atazanavir and lopinavir boosted with ritonavir on cultured human endothelial cells: beneficial effect of pravastatin.
Auclair M; Afonso P; Capel E; Caron-Debarle M; Capeau J
Antivir Ther; 2014; 19(8):773-82. PubMed ID: 24535489
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study.
Antinori A; Meraviglia P; Monforte Ad; Castagna A; Mussini C; Bini T; Gianotti N; Rusconi S; Colella E; Airoldi G; Mancusi D; Termini R
Drug Des Devel Ther; 2016; 10():1589-603. PubMed ID: 27226708
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of tipranavir versus darunavir as a salvage therapy in HIV-1 treatment-experienced patients.
Domínguez-Hermosillo JC; Mata-Marin JA; Herrera-González NE; Chávez-García M; Huerta-García G; Nuñez-Rodríguez N; García-Gámez JG; Jiménez-Romero A; Gaytán-Martínez JE
J Infect Dev Ctries; 2016 Sep; 10(9):982-987. PubMed ID: 27694731
[TBL] [Abstract][Full Text] [Related]
40. Unveiling the basis of antiretroviral therapy-induced osteopenia: the effects of Dolutegravir, Darunavir and Atazanavir on osteogenesis.
Cazzaniga A; Scrimieri R; Galli M; Maier J; Rusconi S
AIDS; 2021 Feb; 35(2):213-218. PubMed ID: 33394669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
